Endonovo Therapeutics (ENDV) 10-K/A 15 Jun 15 2014 FY Annual report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Jun. 15, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	ENDONOVO THERAPEUTICS, INC.
Entity Central Index Key	1528172
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Document Type	10-K
Document Period End Date	31-Dec-14
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	Yes
Entity Current Reporting Status	No
Entity Filer Category	Smaller Reporting Company
Entity Public Float	$0
Entity Common Stock, Shares Outstanding		98,797,026

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets
Cash	$988	$3,255
Other current assets	2,000
Total Current Assets	2,988	3,255
Property Plant and Equipment, net	42,601	58,338
Intangible Assets		12,000
Total Assets	45,589	73,593
Current Liabilities
Accounts payable and accrued expenses	3,167,346	3,293,918
Note payable - Current portion	1,096,602	604,416
Notes payable - related party	291,000	110,086
Total Current Liabilities	4,554,948	4,008,420
Note payable - less current portion	28,646	42,386
Acquisition payable	155,000	155,000
Total Liabilities	4,738,594	4,205,806
Shareholders' Deficit
Common stock, $0.0001 par value, 81,425,957 and 832,223 shares issued and outstanding, respectively	8,143	832
Additional paid-in capital	1,593,297	1,192,845
Stock subscriptions	-1,570
Accumulated deficit	-6,292,875	-5,333,381
Total Shareholders' Deficit	-4,693,005	-4,132,213
Total Liabilities and Shareholders' Deficit	$45,589	$73,593

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Common stock, par value	$0.00	$0.00
Common stock, shares issued	81,425,957	832,223
Common stock, shares outstanding	81,425,957	832,223

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Revenues, net	$24,192	$22,896
Cost of goods sold	15,485	13,993
Gross profit	8,707	8,903
Operating Expenses	2,199,919	2,437,630
Operating Loss	-2,191,212	-2,428,727
Other Income (Expense)
Other income	1,410,550	1,843
Interest expense, net	-178,832	-267,577
Other expenses		-197,801
Loss Before Provision for Income Taxes	-959,494	-2,892,262
Provision for Income Taxes		532
Net Loss	($959,494)	($2,892,794)
Basic and diluted loss per common share	($0.03)	($3.96)
Weighted average common share outstanding - basic and diluted	30,288,009	730,527

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders Equity Deficit (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Subscription Receivable [Member]	Retained Earnings [Member]
Beginning balance at Dec. 31, 2012	($1,881,155)	$54	$559,378		($2,440,587)
Beginning balance, shares at Dec. 31, 2012		536,927
Share issued for service rendered	482,060	19	482,041
Share issued for service rendered, shares		191,046
Unearned stock compensation
Shares issued with notes payable	153,376	4	153,372
Shares issued with notes payable, shares		41,250
Acquisitions		6	6,294
Acquisitions, shares	63,000	63,000
Shares forfeited, shares	-21,602
Net loss	-2,892,794				-2,892,794
Ending balance at Dec. 31, 2013	-4,132,213	83	1,201,085		-5,333,381
Ending balance, shares at Dec. 31, 2013		832,223
Share issued for service rendered	34,436	2,906	31,530
Share issued for service rendered, shares		29,056,275
Shares issued for cash		136	1,434	-1,570
Shares issued for cash, shares		1,362,803
Shares issued for notes payable and extensions	18,617	564	18,053
Shares issued for notes payable and extensions, shares		5,639,750
Shares issued for conversion of payables	5,036	504	4,532
Shares issued for conversion of payables, shares		5,036,453
Share issued for conversion of N/P & Accrued interest	301,604	175	301,429
Share issued for conversion of N/P & Accrued interest, shares		1,744,906
Shares issued for conversion of accrued compansation	38,794	3,879	34,915
Shares issued for conversion of accrued compansation, shares		38,793,547
Shares issued for equity line of credit	215	22	193
Shares issued for equity line of credit, shares		215,000
Shares forfeited		-126	126
Shares forfeited, shares	-354,722	-1,257,500
Net loss	-959,494				-959,494
Ending balance at Dec. 31, 2014	($4,693,005)	$8,143	$1,593,297	($1,570)	($6,292,875)
Ending balance, shares at Dec. 31, 2014		81,425,957

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities:
Net Loss	($959,494)	($2,892,794)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	15,737	11,964
Impairment expense		197,801
Fair value of equity issued for services	34,436	482,060
Amortization of note discount	18,832	147,779
Gain on extinguishment of liabilities	-1,410,550
Changes in operating assets and liabilities:
Account receivable		300
Other assets	10,000
Accounts payable and accrued expenses	1,381,743	1,795,474
Net Cash Used in Operating Activities	-909,296	-257,416
Cash Flow From Investing Activities:
Net cash received in acquisition of subsidiary		4,119
Net Cash Provided by Investing Activities		4,119
Cash Flows From Financing Activities
Proceeds from the issuance of notes payable	935,500	275,000
Payments on notes payable	-28,471	-19,328
Net Cash Provided by Financing Activities	907,029	255,672
Net Increase (Decrease) in Cash	-2,276	2,455
Cash, Beginning of Period	3,255	800
Cash, End of Period	988	3,255
Supplemental disclosure of cash flow information:
Cash paid for interest		219
Cash paid for income taxes		532
Noncash investing and financing activities
Notes payable converted to equity	268,156
Accrued interest reclassified to debt	12,750	43,153
Accrued interest converted to equity	33,448
Debt acquired in purchase of property, plant and equipment		5,000
Debt acquired in acquisition		194,150
Shares issued in acquisition		6,300
Shares issued with debt	$18,053	$153,376

Organization_and_Nature_of_Bus

Organization and Nature of Business	12 Months Ended
	Dec. 31, 2014
Organization and Nature of Business [Abstract]
Organization and Nature of Business	Note 1 - Organization and Nature of Business
	Endonovo Therapeutics, Inc. and Subsidiaries (the “Company” or “ETI”) operates in two business segments: 1) intellectual property licensing and commercialization; and 2) biomedical research and development which has included the development of the TVEMF device which has been the source of all revenues in the current year.
	On January 22, 2014 Hanover Portfolio Acquisitions, Inc. (the "Company") received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50% of the total issued and outstanding voting power of the Company approving an amendment to the Company's Certificate of Incorporation to change the name of the Company from “Hanover Portfolio Acquisitions, Inc.” to “Endonovo Therapeutics, Inc.”  The name change was affected pursuant to a Certificate of Amendment (the “Certificate of Amendment”), filed with the Secretary of State of Delaware on January 24, 2014.
	Acquisition of Aviva
	On April 2, 2013, the Company entered into an Acquisition Agreement (the “Acquisition Agreement”) with (i) The Aviva Companies Corporation (“Aviva”) and (ii) all of the shareholders of Aviva (the “Shareholders”) pursuant to which the Company acquired all of the outstanding shares of Aviva in exchange for the issuance of 6,000,000 shares of our common stock, par value $0.0001 per share to the Shareholders (the “Share Exchange”). Aviva is an early stage company seeking to identify, and commercialize intellectual property in healthcare and technology. Aviva works closely with inventors of IP in both the United States and Israel.
	The acquisition date fair value of the consideration transferred pursuant to the Acquisition Agreement totaled $6,000. The preliminary goodwill recorded for the acquisition was $101,957.
	The following table summarizes the allocation of the purchase price on April 2, 2013 to the estimated fair values of the assets acquired and liabilities assumed in the acquisition:
	Cash	$
		3,743
	Accounts receivable	300
	Notes payable	-100,000
	Fair market value of net assets acquired	-95,957
	Goodwill	101,957
	Total consideration	$
		6,000
	Goodwill of $101,957 was comprised of the fair value of the stock issued in the merger of $6,000 less net assets acquired of $95,957. The Company determined goodwill to be fully impaired as of December 31, 2013. The results of Aviva have been included in the Company’s consolidated financial results for the period from April 2, 2013 through December 31, 2013.
	Acquisition of WeHealAnimals, Inc.
	On November 16, 2013 the Company entered into an Asset Purchase Agreement with WeHealAnimals, Inc. (“WHA”). Pursuant to the agreement the Company issued 300,000 shares of common stock and a $96,000 note payable to WHA in exchange for all of the outstanding shares of WHA as well all rights to the acquired company’s assets, licenses, patents and applications.  WHA is an early stage company seeking to identify, and commercialize intellectual property in healthcare and technology.
	The acquisition date fair value of the consideration transferred pursuant to the Asset Purchase Agreement totaled $96,300. The preliminary goodwill recorded for the acquisition was $95,844. The initial fair values set forth below may be adjusted as additional information is obtained through the measurement period of the transaction and change the fair value allocation as of the acquisition date.
	The following table summarizes the allocation of the purchase price on November 16, 2013 to the estimated fair values of the assets acquired and liabilities assumed in the acquisition:
	Cash	$
		456
	Fair market value of net assets acquired	456
	Goodwill	95,844
	Total consideration	$
		96,300
	Goodwill of $96,300 was comprised of the fair value of the stock issued in the acquisition of $300 and notes payable of $96,000 less net assets acquired of $456. The Company determined goodwill to be fully impaired as of December 31, 2013. The results of WHA have been included in the Company’s consolidated financial results for the period from November 16, 2013 through December 31, 2013.
	Basis of Presentation and Principles of Consolidation
	The consolidated financial statements of the Company include the accounts of ETI, IPR as of March 14, 2012, Aviva as of April 2, 2013 and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidated.
	Going Concern
	These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements.  The Company has recurring net losses and working capital deficits. The Company has raised approximately $940,000 in debt financing for the year ended December 31, 2014.  The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations.  However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern.  No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management has implemented its business plan to materialize revenues from it license agreements, has initiated a private placement offering to raise capital through the sale of its common stock and is seeking out profitable companies.  Although, uncertainty exists as to whether the Company will be able generate enough cash from operations to fund the Company’s working capital needs or raise sufficient capital to meet the Company’s obligations as they become due, no adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Critical estimates include the value of its debt portfolios, the useful lives of property and equipment, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates.  Actual results could differ from these estimates.
	Cash and Cash Equivalents
	The Company considers all highly liquid financial instruments with maturity of three months or less to be cash equivalents. As of December 31, 2014 and 2013, the Company had cash and cash equivalents of $988 and 3,255, respectively.
	Credit Risk
	Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash. The Company primarily places its cash with high-credit quality financial institutions. Cash deposits up to approximately $250,000 are federally insured. From time-to-time the Company could have deposits in excess of the insured amounts. As of December 31, 2014 and 2013 the Company had no uninsured deposits.
	Property plant and equipment
	Property, plant and equipment are stated at cost.  Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range between five and seven years.  Expenditures for repairs and maintenance are expensed as incurred.
	The majority of the Company’s property, plant and equipment is the Company automobile. As of December 31, 2014 and 2013, the cost basis of the Company’s property, plant and equipment was $74,403 with accumulated depreciation of $31,802 and $16,065, respectively. The assets are being depreciated over their estimated useful life of 5 years. The depreciation expense for the years ended December 31, 2014 and 2013 was $15,737 and $11,964, respectively.
	Impairment of Long-lived Assets
	The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows generated from the asset group to the recorded value of the asset group. If impairment is indicated, the asset is written down to its estimated fair value.
	Impairment of Goodwill
	The Company calculates goodwill as the difference between the acquisition date fair value of the estimated consideration paid in the acquisitions and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is generally subject to an impairment test annually or more frequently if an event or circumstance indicates that an impairment loss may have been incurred. The Company determined the consolidated goodwill balance of $197,801 to be impaired as of December 31, 2013, and charged such amount to other expenses.
	Revenue Recognition
	The Company recognizes revenue on sales of medical equipment when services are performed and revenues are realizable in accordance with FASB ASC 605-10.
	Stock-Based Compensation
	The Company measures stock-based compensation cost at the grant date based on the fair value of the award and recognizes it as expense, net of estimated forfeitures, over the vesting or service period, as applicable, of the stock award using the straight-line method. Because our common stock is thinly traded, we have made estimates of the fair value of the common stock based not only on market prices but other factors such as financial condition and results of operations.
	Income Taxes
	The Company records a tax provision for the anticipated tax consequences of its reported results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and income tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.
	The Company has adopted ASC Topic 740, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC Topic 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provides guidance on derecognition of tax benefits, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure and transition. The Company has determined that the adoption did not result in the recognition of any liability for unrecognized tax benefits and that there are no unrecognized tax benefits that would, if recognized, affect the Company’s effective tax rate.  Based on the Company’s review of its tax positions as of December 31, 2014 and 2013, no uncertain tax positions have been identified.
	The Company has elected to include interest and penalties related to uncertain tax positions as a component of income tax expense. To date, no penalties or interest has been accrued.
	Tax years through 2010 and 2009, respectively, are open and subject to examination by federal and state taxing authorities. The Company is not currently under examination, nor has it been notified of a pending examination.
	Segments
	For the Years ended December 31, 2014 and 2013, the Company operated in one segment. See Note 7
	Net Income (Loss) per Share
	Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive securities using the if-converted method, and assumes the exercise or vesting of other dilutive securities, such as options, warrants and restricted stock using the treasury stock method. For the years ended December 31, 2014 and 2013 the Company did not have dilutive securities.
	Fair Value of Financial Instruments
	The Company has adopted accounting standards that define fair value, establish a framework for measuring fair value in accordance with existing generally accepted accounting principles, and expand disclosures about fair value measurements. Assets and liabilities recorded at fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories are as follows:
	Level Input:	Input Definition:
	Level I	Inputs are unadjusted, quoted prices for the identical assets or liabilities in active markets at the measurement date.
	Level II	Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.
	Level III	Unobservable inputs that reflect management's best estimate of what market participants would use in pricing the asset or liability at the measurement date.
	The carrying amount of certain of the Company’s financial instruments approximates fair value due to the relatively short maturity of such instruments. The fair value of notes payable is not considered to be significantly different than its carrying amount because the stated rates for such debt reflect current market rates and conditions.
Recent Accounting Standard Updates
The Company is not aware of any recently issued accounting pronouncements that when adopted will have a material effect on the Company’s financial position or result of its operations.

License_Agreements

License Agreements	12 Months Ended
	Dec. 31, 2014
License Agreements [Abstract]
License Agreements	Note 2 - License Agreements
	CPAIR, Inc.
	Effective November 11, 2011, IPR entered into an Exclusive License Agreement with CPAIR, Inc. (“CPaiR”) to acquire the rights to market and distribute certain intellectual property on a worldwide basis except for the United States.  The terms of the license agreement shall be for the greater of the life of the provisional patents, for the technology, or twenty-one years.  The term shall automatically renew for an additional one year term unless either party notifies the other that it does not desire to renew the license agreement ninety days before the then-current term of the license agreement expires.  Under the Exclusive License Agreement, if IPR enters into a sublicense agreement, IPR is required to pay CPaiR 20% of royalties received by IPR. If IPR elects to distribute the product, without sublicenses, then CPaiR receives 10% of gross revenues. Also, IPR is required to pay to CPaiR 20% of any upfront license fee actually received by IPR in connection with the CPaiR intellectual property and 20% of the quarterly revenue actually received by IPR in connection with such intellectual property.  If IPR does not pay a minimum of $1,000,000 to CPaiR within a period of three years from the Effective date, the license agreement will terminate. IPR has the right to pay the difference between the amounts paid by IPR and the minimum payment of $1,000,000. Under the terms of the agreement, IPR was not required to pay an upfront license fee.
	American Cryostem Corp.
	Effective January 27, 2012, IPR entered into a License Agreement with American Cryostem Corp. ("ACSC") to acquire the rights to and to distribute certain intellectual property in China and Brazil. The term of the License Agreement shall be for one year.  The term shall automatically renew for an additional one-year term unless either party notifies the other that it does not desire to renew the License Agreement. Under the License Agreement, any distributer or sub-licensee, engaged by IPR, must pay a 25% of its quarterly gross revenue. Of the 25% of quarterly gross revenue, IPR and ACSC split 50/50. In the event that IPR receives any upfront license fee from a sub-licensee, IPR is required to pay to ACSC 50% of any upfront license fee actually received. Under the terms of the agreement, IPR was not required to pay an upfront license fee.

Notes_payable

Notes payable	12 Months Ended
	Dec. 31, 2014
Notes Payable [Abstract]
Notes payable	Note 3 - Notes payable
	Promissory Notes
	In October 2013, the Company initiated a private placement (“Private Plaement”) for up to $500,000 of financing by the issuance of notes payable at a minimum of $25,000. The notes bear interest at 10% per annum and are due and payable with accrued interest one year from issuance.  Also, the Company agreed to issue 125,000 shares of its common stock for each unit. In July 2014, the Company initiated a private placement for up to $500,000 of financing by the issuance of notes payable at a minimum of $25,000. The notes bear interest at 10% per annum and are due and payable with accrued interest one year from issuance.  Also, the Company agreed to issue 50,000 shares of its common stock for each unit. As of December 31, 2014 and 2013, the company has outstanding promissory notes for an aggregate proceeds of approximately $1,150,000. In addition, the Company issued 7,430,156 shares of its common stock as loan fees and extension fees related to the issuance of these notes (See Note 3 – Common Stock “Reverse Split”).  These shares were valued at their issuance date fair market value of approximately $172,000, which was recorded as a note discount.  These notes carry an interest rate of 10% per annum.  The interest is payable in arrears on their maturity dates between January and September 2015.
	During the year ended December 31, 2014, the Company entered into three Allonge agreements (“Allonge Agreements”) with three note holders. The Allonge Agreement provides for the note holders to extend the maturity dates of their notes and the option to convert the notes into shares of the Company’s common stock at a conversion rate of $0.50 per share. The total shares issuable under the conversion feature were 602,806 in the aggregate. In connection with the Allonge Agreements the holders where issued in the aggregate 1,142,100 shares of the Company’s common stock. Upon the execution of the Allonge Agreements, each of the holders elected to convert the notes.
	In aggregate, As of December 31, 2014, the principal balance of the Private Placement notes payable was approximately $956,000 net of the unamortized portion of note discounts created from shares issued with notes payable of approximately $1,100. Amortization of note discounts was approximately $19,000 for the year ended December 31, 2014.
	During the year ended December 31, 2014, the Company issued three separate promissory notes to two shareholders for an aggregate principal amount of $195,000. The Notes carry an interest rate of 12% per annum and maturity dates in March, September and October 2015 with interest due monthly
	In March 2012, concurrent with the reverse merger with HPA, the Company issued an acquisition payable of $155,000 to the shareholders of HPA that remains outstanding as of December 31, 2014.
	In November 2012, the Company purchased a vehicle for $64,458. The purchase was financed through a note payable for $64,458 at interest of 2.99% per annum with sixty payments of $1,060 per month.
	As of September 30, 2014, future minimum payments due fiscal years due on notes payable are as follows:
	As of December 31,	Non-Related Parties	Related Parties	Total
	2015	$	$	$
		1,098,042	291,000	1,389,042
	2016	12,031	-	$
				12,031
	2017	12,395	-	$
				12,395
	2018	4,220	-	$
				4,220
	2019	-	-	$
				-
	Thereafter	155,000	-	$
				155,000
	Total	$	$	1,572,688
		1,281,688	291,000

Shareholders_Deficit

Shareholders' Deficit	12 Months Ended
	Dec. 31, 2014
Shareholders' Deficit [Abstract]
Shareholders' Deficit	Note 4 - Shareholders’ Deficit
	Common Stock
	On June 18, 2013, Hanover Portfolio Acquisitions, Inc. (the "Company") received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50% of the total issued and outstanding shares of voting stock of the Company approving an amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of the Company's Common Stock, from 75,000,000 shares to 250,000,000 shares.  The increase in authorized shares was effected pursuant to a Certificate of Amendment (the “Certificate of Amendment”), filed with the Secretary of State of Delaware on September 20, 2013, and a Certificate of Correction to the of Certificate of Amendment (the “Certificate of Correction”, together with the Certificate of Amendment, the “Certificates”), filed with the Secretary of State of the State of Delaware on September 26, 2013 to correctly state the par value of the Company’s Common Stock as $0.0001 per share.  Definitive confirmation of the filing of the Certificates was received on October 10, 2013.
	Series AA Preferred Shares
	On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.0001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof.
	Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company.  As of December 31, 2013, there were 1,000 shares of Series AA Preferred stock outstanding.
	Reverse Spilt
	On April 28, 2014, we concluded the process of changing our corporate name to Endonovo Therapeutics, Inc. and began trading under the symbol ENDV.  The Company has enacted a reverse stock split effective May 15, 2014.  All share or per share numbers in this report have been adjusted for the reverse stock split.
	Issuance of Common Stock
	The Company has entered into consulting agreements with various consultants for service to be provided to the Company. The agreements stipulate a monthly fee and a certain number of shares that the consultant vests in over the term of the contract. The consultant is issued a prorated number of shares of common stock at the beginning of the contract, which the consultant earns over a three-month period. At the anniversary of each quarter, the consultant is issued a new allotment of common stock. In accordance with ASC 505-50 – Equity-Based Payment to Non-Employees, the common stock shares issued to the consultant are valued upon their vesting, with interim estimates of value as appropriate during the vesting period.
	The shares of common stock that have vested through January 2013 were valued based on a valuation performed by an independent valuation firm as the Company had no active market for its shares prior to that time. The Company’s shares began trading in January 2013; as a result the Company utilized market value for its stock when valuing its common stock for the three months ended March 31, 2013. During the second quarter of 2013, the Company revalued the shares based on low trading volume to $0.001. As of December 31, 2014, the total awards granted were 15,292,574 shares with 3,253,264 shares vested and issued, 376,324 forfeited with the 11,662,986 shares unvested. The total expense recorded for the years ended December 31, 2014 and 2013, was $2,991 and $1,407, respectively.
	The following table presents the unissued shares related to the stock grants:
		Number of		Estimated Market
		Shares		Value
	Balance January 1, 2013	198,418
	New Contracts	3,262,518
	Vested	-140,651
	Forfeitures	-21,602
	Balance December 31, 2013	3,298,683		$3,299
	New Contracts	11,710,400
	Vested	(2,991,375	)
		-354,722
	Balance December 31, 2014	11,662,986		$11,663
	During the year ended December 31, 2014, the Company issued an additional 26,064,490 shares of its common stock at a fair value of $26,064 for services rendered
	During the year ended December 31, 2014, the Company had the following share issuances of its common stock at a current market value of $0.001 per share:
	·
	Sold 1,362,803 shares of its common stock for total consideration of $1,570. The Company has recorded the purchase price as a stock subscription receivable, which has been classified as stockholders equity as the Company has not received the consideration as of the issuance of these financial statements.
	·
	Converted $5,036 of its accounts payable into 5,036,453 shares of its common stock.
	·
	Converted $38,794 of accrued compensation into 38,793,547 shares of its common stock
	During the year ended December 31, 2013, the Company issued 63,000 of its common stock at a fair value of $6,300 in connection with business combination transactions.

Other_Income

Other Income	12 Months Ended
	Dec. 31, 2014
Other Income [Abstract]
Other Income	Note 5 - Other Income
	During the year ended December 31, 2014, the Company entered into agreements with a number of consultants to settle amounts due under the consulting agreements. Prior to these agreements, the Company owed the consultants $1,524,666 of deferred compensation and $199,800 of interest accrued on one of the consultants unpaid balance monthly over the term that the compensation was not paid. The Company has reduced the deferred compensation and accrued interest payable to $313,916. The $1,410,550 has been recognized as other income in the accompanying consolidated statement of operation for the year ended December 31, 2014.

Income_taxes

Income taxes	12 Months Ended
	Dec. 31, 2014
Income taxes [Abstract]
Income taxes	Note 6 - Income taxes
	The Company files income tax returns with the Internal Revenue Service (“IRS”) and various state jurisdictions. For jurisdictions in which tax filings are prepared, the Company is subject to income tax examinations by state tax authorities and federal tax authorities for all tax years.
	The deferred tax assets are mainly comprised of net loss carryforwards. As of December 31, 2014, the Company had approximately $2,342,939 of federal net operating loss carryforwards, that it can use to offset a certain amount of taxable income in the future. These federal net operating loss carryforwards expire through 2034.  The resulting deferred tax asset is offset by a 100% valuation allowance due to the uncertainty of its realization.
	A reconciliation of the provision for income tax expense with the expected income tax computed by applying the federal statutory income tax rate to income before provision for income taxes was as follows for the years ended December 31, 2014 and 2013:
		2014		2013
	Income tax computed at federal statutory tax rate	-34	%	-34	%
	Change in valuation allowance	39.8	%	39.8	%
	State taxes, net of federal benefit	-5.8	%	-5.8	%
	Total	0	%	0	%
	The primary difference between income tax expense attributable to continuing operations and the amount of income tax expense that would result from applying domestic federal statutory rates to income before provision for income taxes relates to the change in the valuation allowance.
	The Company has adopted the accounting standards that clarify the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.  In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. Our policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. Interest and penalties totaled $0 for the years ended December 31, 2014 and 2013.

Discontinued_Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2014
Discontinued Operations [Abstract]
Discontinued Operations	Note 7 - Discontinued Operations
	During the year ended December 31, 2013, the Company discontinued its efforts in the debt portfolio management segment. The results of historical operations are recorded as discontinued operations in the Company’s Consolidated Statements of Operations. Additionally, the cash flows from this segment are reflected separately as cash flows from discontinued operations in the Company’s Consolidated Statements of Cash Flows.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 8 - Commitments and Contingencies
	Legal matters
	The Company may become involved in various legal proceedings in the normal course of business. The Company is not a party to any legal proceedings as of December 31, 2014.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	Note 9 - Subsequent Events.
	From January 1, 2015 through April 1, 2015 an aggregate of 2,265,000 shares of restricted common stock were issued as compensation to independent contractors.
	From January 1, 2015 through April 1, 2015, the Company issued $162,500 in notes payable and issued 325,000 shares of its restricted common stock pursuant to a Private Placement Memorandum and private offerings.
	January 13, 2015and February 6, 2015 the Company issued an aggregate of 125,000 shares of its restricted common stock were issued as compensation to an independent contractor under contract with OTB Healing, LLC.
	From January 1, 2015 through April 1, 2015, the Company issued an aggregate of 181,231 shares of its restricted common stock pursuant to Securities Purchase Agreements.
	On February 6, 2014, the Company issued an aggregate of 500,000 shares of restricted common stock as compensation for the services provided by a vendor.
	On March 6, 2015, the Company issued an aggregate of 34,286 shares of restricted common stock as compensation for the services provided by a vendor.
	From March 1st to March 31st 2015, the Company converted three note holders with a total of $320,406 of debt which was one year old or older for an aggregate of 12,200,591 shares of stock.  These shares are subject to a leak-out provision where not more than 3,000 shares may be sold in the open market in any given day.
	As a result of these issuances the total number of shares outstanding is 97,050,729.
	On January 20, 2015 the Company entered into an Equity Purchase Agreement (“EPA”) and a Registration Rights Agreement (“RRA”) with Kodiak Capital Group, LLC (“Kodiak”) in order to establish a source of funding for us.  In connection with the EPA, the Company issued 215,000 shares of common stock to Kodiak as a commitment fee in 2014. Under the EPA, Kodiak has agreed to provide us with up to $3,000,000 of funding upon effectiveness of a registration statement on Form S-1. Following effectiveness of the registration statement, the Company can deliver puts to Kodiak under the EPA under which Kodiak will be obligated to purchase shares of the Company’s common stock based on the investment
	amount specified in each put notice, which investment amount may be any amount up to $3,000,000 less the investment amount received by us from all prior puts, if any. Puts may be delivered by us to Kodiak until the earlier of June 30, 2016 or the date on which Kodiak has purchased an aggregate of $3,000,000 of put shares. The Company filed the required Form S-1 on February 13, 2015 and the Form S-1 has not been ordered effective by the Securities and Exchange Commission.  Accordingly, the Company has not realized any funds under the EPA.
	On February 10, 2015, the Company received a related party loan for $50,000 at 12% interest payable monthly with a maturity date of June 4th, 2015.

Organization_and_Nature_of_Bus1

Organization and Nature of Business (Policies)	12 Months Ended
	Dec. 31, 2014
Organization and Nature of Business [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation
	The consolidated financial statements of the Company include the accounts of ETI, IPR as of March 14, 2012, Aviva as of April 2, 2013 and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidated.
Going Concern	Going Concern
	These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements.  The Company has recurring net losses and working capital deficits. The Company has raised approximately $940,000 in debt financing for the year ended December 31, 2014.  The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations.  However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern.  No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management has implemented its business plan to materialize revenues from it license agreements, has initiated a private placement offering to raise capital through the sale of its common stock and is seeking out profitable companies.  Although, uncertainty exists as to whether the Company will be able generate enough cash from operations to fund the Company’s working capital needs or raise sufficient capital to meet the Company’s obligations as they become due, no adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Critical estimates include the value of its debt portfolios, the useful lives of property and equipment, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates.  Actual results could differ from these estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company considers all highly liquid financial instruments with maturity of three months or less to be cash equivalents. As of December 31, 2014 and 2013, the Company had cash and cash equivalents of $988 and 3,255, respectively.
Credit Risk	Credit Risk
	Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash. The Company primarily places its cash with high-credit quality financial institutions. Cash deposits up to approximately $250,000 are federally insured. From time-to-time the Company could have deposits in excess of the insured amounts. As of December 31, 2014 and 2013 the Company had no uninsured deposits.
Property plant and equipment	Property plant and equipment
	Property, plant and equipment are stated at cost.  Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range between five and seven years.  Expenditures for repairs and maintenance are expensed as incurred.
	The majority of the Company’s property, plant and equipment is the Company automobile. As of December 31, 2014 and 2013, the cost basis of the Company’s property, plant and equipment was $74,403 with accumulated depreciation of $31,802 and $16,065, respectively. The assets are being depreciated over their estimated useful life of 5 years. The depreciation expense for the years ended December 31, 2014 and 2013 was $15,737 and $11,964, respectively.
Impairment of Long-lived Assets	Impairment of Long-lived Assets
	The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows generated from the asset group to the recorded value of the asset group. If impairment is indicated, the asset is written down to its estimated fair value.
Impairment of Goodwill	Impairment of Goodwill
	The Company calculates goodwill as the difference between the acquisition date fair value of the estimated consideration paid in the acquisitions and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is generally subject to an impairment test annually or more frequently if an event or circumstance indicates that an impairment loss may have been incurred. The Company determined the consolidated goodwill balance of $197,801 to be impaired as of December 31, 2013, and charged such amount to other expenses.
Revenue Recognition	Revenue Recognition
	The Company recognizes revenue on sales of medical equipment when services are performed and revenues are realizable in accordance with FASB ASC 605-10.
Stock-Based Compensation	Stock-Based Compensation
	The Company measures stock-based compensation cost at the grant date based on the fair value of the award and recognizes it as expense, net of estimated forfeitures, over the vesting or service period, as applicable, of the stock award using the straight-line method. Because our common stock is thinly traded, we have made estimates of the fair value of the common stock based not only on market prices but other factors such as financial condition and results of operations.
Income Taxes	Income Taxes
	The Company records a tax provision for the anticipated tax consequences of its reported results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and income tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.
	The Company has adopted ASC Topic 740, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC Topic 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provides guidance on derecognition of tax benefits, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure and transition. The Company has determined that the adoption did not result in the recognition of any liability for unrecognized tax benefits and that there are no unrecognized tax benefits that would, if recognized, affect the Company’s effective tax rate.  Based on the Company’s review of its tax positions as of December 31, 2014 and 2013, no uncertain tax positions have been identified.
	The Company has elected to include interest and penalties related to uncertain tax positions as a component of income tax expense. To date, no penalties or interest has been accrued.
	Tax years through 2010 and 2009, respectively, are open and subject to examination by federal and state taxing authorities. The Company is not currently under examination, nor has it been notified of a pending examination.
Segments	Segments
	For the Years ended December 31, 2014 and 2013, the Company operated in one segment. See Note 7
Net Income (Loss) per Share	Net Income (Loss) per Share
	Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive securities using the if-converted method, and assumes the exercise or vesting of other dilutive securities, such as options, warrants and restricted stock using the treasury stock method. For the years ended December 31, 2014 and 2013 the Company did not have dilutive securities.
Fair value measurements	Fair Value of Financial Instruments
	The Company has adopted accounting standards that define fair value, establish a framework for measuring fair value in accordance with existing generally accepted accounting principles, and expand disclosures about fair value measurements. Assets and liabilities recorded at fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories are as follows:
	Level Input:	Input Definition:
	Level I	Inputs are unadjusted, quoted prices for the identical assets or liabilities in active markets at the measurement date.
	Level II	Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.
	Level III	Unobservable inputs that reflect management's best estimate of what market participants would use in pricing the asset or liability at the measurement date.
	The carrying amount of certain of the Company’s financial instruments approximates fair value due to the relatively short maturity of such instruments. The fair value of notes payable is not considered to be significantly different than its carrying amount because the stated rates for such debt reflect current market rates and conditions.
Recent Accounting Standard Updates	Recent Accounting Standard Updates
	The Company is not aware of any recently issued accounting pronouncements that when adopted will have a material effect on the Company’s financial position or result of its operations.

Organization_and_Nature_of_Bus2

Organization and Nature of Business (Tables)	12 Months Ended
	Dec. 31, 2014
Organization and Nature of Business [Abstract]
Schedule of purchase price stimated fair values of the assets acquired and liabilities
	Cash	$
		3,743
	Accounts receivable	300
	Notes payable	-100,000
	Fair market value of net assets acquired	-95,957
	Goodwill	101,957
	Total consideration	$
		6,000
	Cash	$
		456
	Fair market value of net assets acquired	456
	Goodwill	95,844
	Total consideration	$
		96,300

Notes_payable_Tables

Notes payable (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Payable [Abstract]
Future minimum payments
	As of December 31,	Non-Related Parties	Related Parties	Total
	2015	$	$	$
		1,098,042	291,000	1,389,042
	2016	12,031	-	$
				12,031
	2017	12,395	-	$
				12,395
	2018	4,220	-	$
				4,220
	2019	-	-	$
				-
	Thereafter	155,000	-	$
				155,000
	Total	$	$	1,572,688
		1,281,688	291,000

Shareholders_Deficit_Tables

Shareholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2014
Shareholders' Deficit [Abstract]
Schedule of unissued shares related to stock granted
		Number of		Estimated Market
		Shares		Value
	Balance January 1, 2013	198,418
	New Contracts	3,262,518
	Vested	-140,651
	Forfeitures	-21,602
	Balance December 31, 2013	3,298,683		$3,299
	New Contracts	11,710,400
	Vested	(2,991,375	)
		-354,722
	Balance December 31, 2014	11,662,986		$11,663

Income_taxes_Tables

Income taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income taxes [Abstract]
Schedule of federal statutory income tax
		2014		2013
	Income tax computed at federal statutory tax rate	-34	%	-34	%
	Change in valuation allowance	39.8	%	39.8	%
	State taxes, net of federal benefit	-5.8	%	-5.8	%
	Total	0	%	0	%

Organization_and_Nature_of_Bus3

Organization and Nature of Business (Details) (USD $)	0 Months Ended
	Nov. 16, 2013	Apr. 02, 2013	Dec. 31, 2014	Dec. 31, 2013	Nov. 30, 2012
Organization and Nature of Business (Textual)
Cash			$988	$3,255
Notes Payable			1,150,000	1,150,000	64,458
Goodwill	96,300			197,801
Total consideration	300
Acquisition of Aviva [Member]
Organization and Nature of Business (Textual)
Cash		3,743
Accounts receivable		300
Notes Payable		-100,000
Fair Value of Assets Acquired		95,957
Goodwill		101,957
Total consideration		6,000
Acquisition of WeHealAnimals, Inc. [Member]
Organization and Nature of Business (Textual)
Cash	456
Fair Value of Assets Acquired	456
Goodwill	95,844
Total consideration	$96,300

Organization_and_Nature_of_Bus4

Organization and Nature of Business (Details Textual) (USD $)	0 Months Ended	12 Months Ended		0 Months Ended
	Nov. 16, 2013	Dec. 31, 2014	Dec. 31, 2013	Apr. 02, 2013	Nov. 30, 2012
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Total consideration	$300
Goodwill	96,300		197,801
Cash		988	3,255
Notes payable		1,150,000	1,150,000		64,458
Common Stock, Shares, Issued		81,425,957	832,223
Common stock, par value		$0.00	$0.00
Cash deposits		250,000
Property, plant and equipment		74,403
Accumulated depreciation		31,802	16,065
Depreciation expense		15,737	11,964
Debt finance		940,000
Estimated useful lives		5 years
Minimum [Member]
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Estimated useful lives		5 years
Maximum [Member]
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Estimated useful lives		7 years
Wehealanimals, Inc [Member]
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Total consideration	96,300
Goodwill	95,844
Cash	456
Notes payable	96,000
Common Stock, Shares, Issued	300,000
Acquisition Agreement [Member]
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Total consideration				6,000
Goodwill				101,957
Cash				95,957
Fair market value of net assets acquired				$6,000
Common Stock, Shares, Issued				6,000,000
Common stock, par value				$0.00

License_Agreements_Details

License Agreements (Details) (Licensing Agreements [Member], USD $)	0 Months Ended	1 Months Ended
	Nov. 11, 2011	Jan. 27, 2012
CPAIR, Inc [Member]
License Agreement (Textual)
Percentage of royalty received	20.00%
Gross revenues	10.00%
Payment of upfront license fee	20.00%
Quarterly revenue paid to cpair	20.00%
Minimum annual royalty payment	$1,000,000
Effective date	3 years
Minimum amounts paid	$1,000,000
American Cryostem Corp [Member]
License Agreement (Textual)
Gross revenues		25.00%
Payment of upfront license fee		50.00%
Percentage of quarterly gross revenue owed by distributor or sub-licensee		25.00%

Notes_payable_Details

Notes payable (Details) (USD $)	Dec. 31, 2014
Related Party Transaction [Line Items]
2015	$1,389,042
2016	12,031
2017	12,395
2018	4,220
2019
Thereafter	155,000
Total	1,572,688
Non-Related Parties [Member]
Related Party Transaction [Line Items]
2015	1,098,042
2016	12,031
2017	12,395
2018	4,220
2019
Thereafter	155,000
Total	1,281,688
Related Parties [Member]
Related Party Transaction [Line Items]
2015	291,000
2016
2017
2018
2019
Thereafter
Total	$291,000

Notes_payable_Details_Textual

Notes payable (Details Textual) (USD $)	1 Months Ended		12 Months Ended		1 Months Ended
	Nov. 30, 2012	Mar. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Jul. 31, 2014	Oct. 31, 2013
Subsidiary, Sale of Stock [Line Items]
Proceeds from the issuance of notes payable			$935,500	$275,000
Debt instrument interest rate			12.00%
Common stock shares issued			11,710,400	3,262,518
Shares issuable under the conversion feature			602,806
Amortization of debt discount			18,832	147,779
Notes payable	64,458		1,150,000	1,150,000
Debt instrument monthly payment	1,060
Purchase of vehicle	64,458
Stock issued during period value acquistion		155,000
Debt instrument principal amount			195,000
Debt instrument interest percentage			2.99%
Shares issued for conversion of notes payables, shares			1,142,100
Stock issued during period shares related to notes payable			7,430,156
Stock issued during period value related to notes payable			172,000
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of value issue in notes payable					500,000	500,000
Proceeds from the issuance of notes payable					25,000	25,000
Debt instrument interest rate			10.00%		10.00%	10.00%
Common stock conversion price			$0.50
Common stock shares issued					50,000	125,000
Amortization of debt discount			19,000
Debt instrument principal amount			956,000
Unamortization of debt discount			$1,100

Shareholders_Deficit_Details

Shareholders' Deficit (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Shareholders' Deficit [Abstract]
Beginning balance	3,298,683	198,418
New Contracts	11,710,400	3,262,518
Vested	-2,991,375	-140,651
Forfeitures	-354,722	-21,602
Ending balance	11,662,986	3,298,683
Estimated market value, Beginning	$3,299
Estimated market value, Ending	$11,663	$3,299

Shareholders_Deficit_Details_T

Shareholders' Deficit (Details Textual) (USD $)	3 Months Ended	12 Months Ended		0 Months Ended
	Jun. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Jun. 18, 2013	Feb. 22, 2013
Shareholders' Deficit (Textual)
Common stock, par value		$0.00	$0.00
Revaluation of shares based on low trading volume	$0.00
Awards granted		15,292,574
Vested, shares		3,253,264
Unvested, shares		11,662,986
Forfeited, shares		376,324
Total expense		$2,991	$1,407
Shares issued for cash
Shares issued for conversion of accounts payable		5,036
Shares issued for conversion of accrued compansation		38,794
Share issued for service rendered		34,436	482,060
Shares issued in connection with business combination transactions			63,000
Series AA Preferred Shares [Member]
Shareholders' Deficit (Textual)
Preferred stock shares authorized					1,000,000
Preferred stock par value					$0.00
Preferred stock shares outstanding			1,000		100,000
Common Stock [Member]
Shareholders' Deficit (Textual)
Common stock, par value				$0.00
Percentage of common stock issued and outstanding				50.00%
Shares issued for cash		136
Shares issued for cash, shares		1,362,803
Shares issued for conversion of accounts payable		504
Shares issued for conversion of accounts payable, shares		5,036,453
Shares issued for conversion of accrued compansation		3,879
Shares issued for conversion of accrued compansation, shares		38,793,547
Share issued for service rendered		2,906	19
Share issued for service rendered, shares		29,056,275	191,046
Shares issued in connection with business combination transactions			63,000
Common Stock [Member] | Minimum [Member]
Shareholders' Deficit (Textual)
Common stock shares authorized				75,000,000
Common Stock [Member] | Maximum [Member]
Shareholders' Deficit (Textual)
Common stock shares authorized				250,000,000
Subscription Receivable [Member]
Shareholders' Deficit (Textual)
Shares issued for cash		-1,570
Shares issued for conversion of accounts payable
Shares issued for conversion of accrued compansation
Share issued for service rendered

Other_Income_Details

Other Income (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Other Income (Textual)
Deferred compensation	$1,524,666
Accrued interest	199,800
Changes in deferred compensation and accrued interest payable	313,916
Other income	$1,410,550	$1,843

Income_taxes_Details

Income taxes (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income taxes [Abstract]
Income tax computed at federal statutory tax rate	-34.00%	-34.00%
Change in valuation allowance	39.80%	39.80%
State taxes, net of federal benefit	-5.80%	-5.80%
Total	0.00%	0.00%

Income_taxes_Details_Textual

Income taxes (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax [Textual]
Net operating loss carryforwards	$2,342,939
Interest and penalties total	$0	$0
Net operating loss carryforwards expiration date	31-Dec-34

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	12 Months Ended		1 Months Ended		0 Months Ended	1 Months Ended		3 Months Ended	0 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jul. 31, 2014	Oct. 31, 2013	Feb. 10, 2015	Mar. 31, 2015	Jan. 20, 2015	Apr. 01, 2015	Mar. 06, 2015	Feb. 06, 2014	Feb. 06, 2015
Subsequent Events (Textual)
Issuance of notes payable	$935,500	$275,000
Common stock shares issued	11,710,400	3,262,518
Interest rate	12.00%
Private Placement [Member]
Subsequent Events (Textual)
Issuance of notes payable			25,000	25,000
Common stock shares issued			50,000	125,000
Interest rate	10.00%		10.00%	10.00%
Subsequent Event [Member]
Subsequent Events (Textual)
Restricted common stock								2,265,000
Convertible debt						320,406
Aggregate debt converted into commn stock						12,200,591
Debt conversion, description						Company converted three note holders with a total of $320,406 of debt which was one year old or older for an aggregate of 12,200,591 shares of stock. These shares are subject to a leak-out provision where not more than 3,000 shares may be sold in the open market in any given day.
Number of shares outstanding						97,050,729
Common stock shares issued							215,000
Description of equity purchase agreement and registration rights agreement							Under the EPA, Kodiak has agreed to provide us with up to $3,000,000 of funding upon effectiveness of a registration statement on Form S-1. Following effectiveness of the registration statement, the Company can deliver puts to Kodiak under the EPA under which Kodiak will be obligated to purchase shares of the Company’s common stock based on the investment amount specified in each put notice, which investment amount may be any amount up to $3,000,000 less the investment amount received by us from all prior puts, if any. Puts may be delivered by us to Kodiak until the earlier of June 30, 2016 or the date on which Kodiak has purchased an aggregate of $3,000,000 of put shares.
Loan received from related party					50,000
Interest rate					12.00%
Maturity date					4-Jun-15
Subsequent Event [Member] | Restricted Stock [Member]
Subsequent Events (Textual)
Share issued for service, shares									34,286	500,000
Subsequent Event [Member] | Securities Purchase Agreements [Member]
Subsequent Events (Textual)
Restricted common stock								181,231
Subsequent Event [Member] | Limited Liability Company [Member]
Subsequent Events (Textual)
Restricted common stock											125,000
Subsequent Event [Member] | Private Placement [Member]
Subsequent Events (Textual)
Restricted common stock								325,000
Issuance of notes payable								162,500